If you can’t beat me, join me: collaborating oncogenes circumventing senescence and causing cancer

Abstract

death. Signaling routes commonly altered in cancer include the RAS-MAP Kinase and PI3 Kinase (PI3K) pathways. Activation of the first can take place at many levels, most frequently through mutations in members of the RAS and RAF families, while also further upstream receptor tyrosine kinases can be activated by mutation or amplification. PI3K pathway activation occurs largely through mutations in its catalytic subunit PIK3CA or amplification of AKT family members. Additionally, the Phosphatase and Tensin Homolog (PTEN), a phosphatase negatively regulating the PI3K pathway by dephosphorylating the lipid phosphatidylinositol-3,4,5-trisphosphate (PIP3), is inactivated in several tumor types by different mechanisms including mutation, deletion, and epigenetic silencing. Perhaps somewhat counter intuitively, although PI3K is an established downstream effector of RAS in oncogenic transformation, simultaneous mutations in RAS and in the PIK3CA ⁄ PTEN ⁄AKT pathway do occur in human cancer. Consistently, in several mouse models, they have been shown to cooperate in accelerating tumorigenesis. While it is reasonably well understood why mutant RAS and deficiencies in the pRB or p53 pathways collaborate in cancer, it is less clear what the mechanistic basis is for activating mutations at two points in a presumed single signaling pathway, like RAS and PI3K. Kennedy et al. recently reported on a molecular interplay model in which the second oncogene, acting downstream, counteracts the senescence-inducing effect of the first (Kennedy et al.,